EMA Human Medicines Highlights – February 2026

26th February 2026

Summary: The February 2026 edition of Human Medicines Highlights highlights EMA’s recent work and regulatory developments, including a milestone message from Executive Director Emer Cooke reflecting on 2025 achievements; Management Board and pharmaceutical legislation progress; and updates on medicines benefit-risk evaluations and review activities such as the ongoing assessment of Tavneos (for rare autoimmune diseases). It also covers progress on AI principles for medicine development and other important regulatory news relevant to patients, healthcare professionals and industry stakeholders across the EU.

Link: https://ec.europa.eu/newsroom/ema/newsletter-archives/72501

Back to Recent News